News Quantified

RLMD – relmada therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications [Yahoo! Finance]

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.

Relmada Therapeutics (NASDAQ:RLMD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

-0.5%

MISS

-2.4%

MISS

-2.1%

MISS

Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: TRAVERSA SERGIO

Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Ence Chuck

Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Shenouda Maged

Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: GLASSPOOL JOHN

Form 4 RELMADA THERAPEUTICS, For: Dec 12 Filed by: Fedeli Fabiana

Top News Gainers

10/14 Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15 134.0%

10/18 Form 8-K RELMADA THERAPEUTICS, For: Oct 17 52.4%

12/4 Relmada prices $100M equity offering [Seeking Alpha] 49.8%

3/18 Form 4 RELMADA THERAPEUTICS, For: Mar 17 Filed by: CASAMENTO CHARLES J 14.7%

3/16 Form 3 RELMADA THERAPEUTICS, For: Mar 09 Filed by: Wessel Thomas 10.6%

10/28 Form S-3/A RELMADA THERAPEUTICS, 10.5%

3/24 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development 10.0%

5/16 Form D RELMADA THERAPEUTICS, 8.2%

3/31 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety 7.4%

5/15 Form 4 RELMADA THERAPEUTICS, For: May 14 Filed by: Kelly Paul Edward 7.1%

Top News Decliners

10/17 Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18 -18.0%

6/20 Form 8-K RELMADA THERAPEUTICS, For: Jun 14 -16.0%

10/21 Form 8-K RELMADA THERAPEUTICS, For: Oct 15 -12.3%

7/10 Form D/A RELMADA THERAPEUTICS, -10.5%

1/31 Form DEF 14A RELMADA THERAPEUTICS, For: Mar 06 -9.7%

3/9 Form 8-K RELMADA THERAPEUTICS, For: Mar 06 -8.7%

3/9 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development -8.6%

10/24 Form EFFECT RELMADA THERAPEUTICS, -7.1%

5/1 Relmada Therapeutics Inc (OTCMKTS: RLMD) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.0%

4/21 Relmada Therapeutics Inc (OTCMKTS: RLMD) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. -6.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day